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Abstract
Background: Knee Osteoarthritis (KOA) is a heterogeneous pathology characterized by a complex and multifactorial
nature. It has been hypothesised that these differences are due to the existence of underlying phenotypes representing
different mechanisms of the disease.
Methods: The aim of this study is to identify the current evidence for the existence of groups of variables which point
towards the existence of distinct clinical phenotypes in the KOA population. A systematic literature search in PubMed
was conducted. Only original articles were selected if they aimed to identify phenotypes of patients aged 18 years or
older with KOA. The methodological quality of the studies was independently assessed by two reviewers and qualitative
synthesis of the evidence was performed. Strong evidence for existence of specific phenotypes was considered present
if the phenotype was supported by at least two high-quality studies.
Results: A total of 24 studies were included. Through qualitative synthesis of evidence, six main sets of variables
proposing the existence of six phenotypes were identified: 1) chronic pain in which central mechanisms (e.g. central
sensitisation) are prominent; 2) inflammatory (high levels of inflammatory biomarkers); 3) metabolic syndrome (high
prevalence of obesity, diabetes and other metabolic disturbances); 4) Bone and cartilage metabolism (alteration in local
tissue metabolism); 5) mechanical overload characterised primarily by varus malalignment and medial compartment
disease; and 6) minimal joint disease characterised as minor clinical symptoms with slow progression over time.
Conclusions: This study identified six distinct groups of variables which should be explored in attempts to better
define clinical phenotypes in the KOA population.
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Background
Osteoarthritis is the most common form of arthritis; it
constitutes a leading cause of disability in the adult
population [1] with the knee the most affected joint.
Knee Osteoarthritis (KOA) is a heterogeneous pathology
characterized by a complex and multifactorial nature [2].
This multifactorial aetiology contributes to the broad
variation in symptoms presentation and treatment
response that characterize the KOA subjects and consti-
tutes a challenge for the identification of personalized and
effective interventions. Therefore, in order to optimize
treatment effect in KOA, the intervention should address
this variability and should be tailored to specific subgroups
or phenotypes as highlighted in the NICE guidelines on
KOA [3–6]. A phenotype in KOA can be defined as a col-
lection of observable traits (i.e. aetiologic factors, risk fac-
tors) that can identify and characterize a subgroup in a
defined population. The presence of distinct phenotypes
within the KOA patient population would suggest distinct
underlying causes and mechanisms, which could be highly
relevant for understanding and treating the disease [7, 8].
Previous attempts to identify distinctive KOA pheno-
types used different perspectives. Some researchers used
disease progression to determine KOA phenotypes, while
others looked at pain perception or the degeneration
pattern of the cartilage [9–15]. Potentially, hundreds of
phenotypes may be identified depending on the definition
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of phenotypes and on the variables selected. Each ap-
proach can be considered equally valid depending on the
scope. Only studies focusing on the identification of clin-
ical subgroups characterized by different disease mecha-
nisms can be considered useful to improve treatment
allocation and clinical management of the disease. If, as
hypothesized, treatments Are highly effective only in one
sub-type; the therapeutic effect of the intervention will be
lost if tested in KOA population as a whole [4]. Therefore,
the identification of risk and aetiologic factors that can
identify specific clinical subtypes of KOA is an important
starting point for the implementation of phenotyping
research in clinical practice and may be critical for the
improvement of treatment allocation and for the develop-
ment of new treatment strategies.
The aim of this review is therefore to synthesize the
current evidence for the existence of distinct sets of
variables that may suggest the existence of clinical KOA
phenotypes characterized by the presence of different
risk and aetiologic factors.
Methods
Information sources
A systematic literature search was conducted in PubMed
(Medline) for the period from 01/01/1984 to 29/04/
2016. An additional manual search was completed by
ADI from the references of the selected papers.
The research strategy was built up using the following
key words: osteoarthritis, knee, phenotyp*, subgroup,
cluster, “factor analysis”. These terms were combined in
the following way: osteoarthritis AND knee AND (phe-
notyp* OR subgroup OR cluster OR “factor analysis”)
(for further details see Additional file 1-A).
Inclusion criteria
Articles were included if: (1) the population involved
(a subgroup of ) patients over 18 years of age; (2) the
population consisted of patients diagnosed with KOA;
(3) the aim was to identify clinical phenotypes of pa-
tients with KOA; (4) the methodology and analysis
were designed to identify phenotypes (e.g. cluster ana-
lysis using clinical variables) ; (5) the article was an
original research report. Previous systematic reviews
were excluded. In addition to the second criterion,
studies that included patients with hip or hand OA
other than KOA were included if: (1) they used bio-
markers or other measures that are not joint specific,
(2) the KOA subgroup represented more than 60 % of
the sample.
Data selection process
Article selection was made independently by two reviewers
(ADI and MS) based on title and abstract according to the
inclusion criteria. The final selection was made by the same
two independent reviewers based on the full text. Disagree-
ments between the two reviewers were resolved by the
intervention of a third reviewer (SS); this procedure was
adopted for both selection steps.
Assessment of methodological quality (risk of bias)
The methodological quality of the papers was assessed
using an adaption of the standardized Hayden score [16]
(Table 1) to identify the risk of bias affecting the validity
of findings. All papers were reviewed by ADl and MS,
with additional proportional reviews performed by RA,
SM, SS using block allocation with each reviewing 2/3 of
the final papers.
The risk of bias for each area was rated as low, moder-
ate or high [16]. Studies that had a high risk of bias in at
least one of the area assessed were considered to have
an overall high risk of bias and regarded as sources of
low quality evidence used only to support the findings of
other (i.e. high quality) studies. Studies with low to mod-
erate risk of bias and appropriate design were considered
sources of strong evidence.
Data-extraction analysis
The data from each study were extracted by two reviewers
(ADI, MS) and included number of patients, clustering
method and subgroups identified. Additionally, the preva-
lence of each phenotype was extracted where possible.
Identification of phenotypes
In this systematic review we adopted a tailored data ana-
lysis process in order to deal with the broad variation in
the methodologies of the studies included. This process
shares some similarities with the directed content ana-
lysis method [17]. Key variables for each phenotype
reported in the included studies were extracted. Using
the theory and previous evidence, we assigned each key
variable to a category (e.g. biomechanical, inflammatory,
metabolic) indicating the underlying disease mechanism
represented by that specific variable.. Variables (e.g.
radiographic features, pain sensitization) were consid-
ered to suggest similar disease mechanisms and classi-
fied in the same category if: (1) It was specifically stated
by the author of the paper (e.g. two subgroups extracted
from two different studies were reported by the respect-
ive authors as representing the same phenotype); (2) the
association of the reported characteristic to a specific
pathophysiologic mechanism had been reported in previ-
ous studies investigating disease mechanisms and risk
factors (e.g. malalignment consistent with compartment
degeneration has previously been reported as a biomech-
anical mechanism responsible for KOA development).
Each phenotype was then classified in the category indi-
cated by the variable that characterized it. A phenotype
was considered supported by evidence when at least two
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studies with low risk of bias identified a phenotype
under the same category. If a phenotype was reported in
only a single study this was not considered sufficient evi-
dence to include this phenotype in the final list of phe-
notypes identified in this review.
Results
Description of the included studies
The initial literature search identified 841 articles. Three
additional papers were identified through a manual search
of the references. After screening for title and abstract,
781 papers were excluded. The full texts for the remaining
63 articles were assessed for inclusion. From this list, 25
articles matched the inclusion criteria and were included
in the systematic review (Fig. 1) [7–9, 18–39]. For an over-
view of the studies included see Table 2. (For further
details see Additional file 1).
Quality assessment
The quality assessment resulted in 21 papers with low or
moderate risk of bias (considered to be high quality
studies) and four papers with a high risk of bias for at
least one of the six areas reviewed, which were consid-
ered to be low quality studies (Table 3).
Phenotypes
A total of 79 phenotypes were reported in the included
studies. Of those, 42 phenotypes were reported in a single
study only and therefore not taken forward into the quali-
tative evidence synthesis. The remaining 37 subgroups
were matched and combined into six main groups of vari-
ables that suggest the existence of different mechanisms
in the KOA population: chronic pain; inflammatory
mechanisms; metabolic mechanisms of bone and cartil-
age local to the joint, metabolic syndrome; mechanical
Table 1 Adaptation of the Hayden score for the evaluation of the risks of bias
Areas of potential bias Explanation and Adaptation
(1) Participation Source population and characteristic of the sample
(2) Study attrition Loss to follow up
(3) Measurement of prognostic
factorsa
A clear definition or description of the prognostic factor measured is provided and adequately reported.
Adaptation: We considered as prognostic factor the variable chosen in the study to classify the patients
and define the phenotypes
(4) Outcome measurementa A clear definition of the outcome of interest is provided and the outcome methods are valid and reliable.
Adaptation: we considered the variable used to define the difference between subgroups as outcome
measures
(5) Confounding factors Are confounders present in the study; confounding factors are accounted for in the study design
(6) Analysis Data analysis and data presentation
a: areas of potential bias adapted to match the design of the studies included
Fig. 1 Flow chart of the study selection process for eligible studies in the systematic review
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Table 2 Description of the papers
Author Type of research Type of study Analysis Participants Control Subgoups
Chronic pain Inflammatory Metabolic
syndrome
Bone and
cartilage
metabolism
Mechanical
overload
Minimal
joint
disease
Attur 2011 [18] Genetic/gene
expression
Cohort (prosp) complete
-linkage
hierarchical
clustering
1: 41a
2: 36a
3: 86a
1: 25a
2: 0a
3: 12a
- 1: 16/41 = 39 %.
2: 8/36 = 22 %,
3: 33/86 = 38 %
- - - -
Bae 2010 [19] Imaging
(photography)
Cross sectional K-means
cluster
analysis
127 - - - - - 20 %b -
Berry 2010a [20] Biomarker Cohort (prosp) Mann–Whitney
u, χ2, Multiple
regression analysis
117 - - - - Prevalence
not reported
- -
Berry 2010b [21] Biomarker Cohort (prosp) Mann–Whitney u,
Multiple regression
and logistic regression
analysis
117 - - - - - - Prevalence
not reported
Blumnenfeld
2013 [22]
Biomarker Cohort (prosp) Binary logistic
regression analysis
Different in
different
analysis
Different
in different
analysis
- - - Prevalence
not reported
- -
Cruz-Almeida
2013 [23]
Lab experimental
(non-biomech)
Cross-sectional Hierarchical cluster
analysys
194 - 32/194 = 16 % - - - - -
Doss 2007 [24] Biomarker Cross-sectional Mann–Whitney 49 - - 8/49 = 16 % - - - -
Egsgaard
2015 [25]
Biomarker Case control Principal component
analysis/Hierarchical
cluster analysis
216 64 41/212 = 19 % - - - - -
Fernández-Tajes
2014 [26]
Genetics Case control Cluster analysys
(unsupervised)
23 18 - 7/23 = 30 % - - - -
Holla 2013 [27] Epidemiology Cohort (prosp) Latent class
growth analysis
697 - - - - - - 330/697 = 47 %
Jenkins 2015
[28]
Epidemiology Secondary data
analysis
Hierarchical and
k -means cluster
analysis
75 - - - - - - Prevalence not
reported
Kerkhof 2008
[29]
Genetics Cross sectional χ2, OR, ANCOVA,
meta-analysis of
existing cohorts
4993 - - - - - - -
Kinds 2013 [9] Imaging Cohort (prosp) Hierarchical
cluster analysys
336 - - - - - - 108/417 = 26 %
King 2013 [30] Lab experimental
(non-biomech)
Case control ANCOVA 209 107 Subgroups
splitted using
mean value of
womac
(percentage
not reliable)
- - - - -
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Table 2 Description of the papers (Continued)
Knoop 2011 [7] Epidemiology Secondary
data analysis
K-means luster
analysis
842 - 83/841 = 10 %
(only
depression)
- 168/841 = 22 %
(only obese)
- 189/841 = 22 % 140/841 = 17 %
Murphy
2011 [31]
Epidemiology Cross-sectional Hierarchical
cluster analysis
129 - 45/125 = 36 % - - - - -
Otterness
2000 [32]
Biomarker Case control Principal
component
analysis
39 21 - Prevalence not
reported
- Prevalence not
reported
- -
Pereira
2013 [33]
Epidemiology Cross-sectional T-test, OR,
logistic
regression
663 - Prevalence
not reported
- - - - -
Roemer
2012 [34]
Imaging Cross sectional OR 1248 - - - - 1248 subjects/
0,2 %
hypertrophic-
1.3 % atrophic
- -
Sowers
2002 [35]
Biomarker Cohort ANOVA, χ2 1025 - - - 11 %b - - -
Van der Esch
2015 [36]
Epidemiology Secondary
data anlysis
K-means
cluster analysis
551 - 86/551 = 15.6 %
(only depression)
- 81/551 = 15 %
(only obese)
- 114/551 =
20.6 %
154/551 = 28 %
Van Spil
2012 [37]
Biomarker Cohort (prosp) Principal
component
analysis, multiple
linear regression
(interaction terms)
1002 - - Prevalence not
reported
- Prevalence not
reported
- -
Waarsing
2015 [8]
Epidemiology Secondary
data analysis
Latent class
cluster analysis
518 - - - 27 % (group with
hypertension and
higher BMI)
- 15 % (lateral
degeneration)
12 %(previous
injuries)
47 %b
Iijima 2015
[38]
Epidemiology Cross sectional Multiple Logistic
regression Analysis
266 - - - - - 26/266 = 9.7 %
(static + dinamic
malalignment)
-
Kittelson
2015 [40]
Epidemiology Secondary
data analysis
Latent class analysis 3494 - 337/3494 = 9.6 % - - - - -
a: this study is composed of 3 cohorts, the results obtained in the first cohort were replicated in the other two to validate the results
b: Only percentage reported
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overload; and minimal joint disease (Additional file 1:
Table S1 and S2). These mechanisms may be respon-
sible for the disease in specific subgroup or phenotypes.
The six main sets of variables that emerged from the
literature are indicative of different disease aetiology
with the exception of the minimal joint disease pheno-
type that classifies the subjects based on the disease
progression. Only one paper reported negative results,
founding no evidence for the existence of distinct phe-
notypes within the KOA patient population [29]. An
overview of the variables extracted from each paper is
provided in Table 2 and in the Additional file 1.
Chronic pain
Six cross sectional studies with low risk of bias, [7, 23, 31,
33, 36, 40] indicating the central nervous system and alter-
ations in pain neurophysiology as key factors in the
disease pathophysiology, were considered to support a
chronic pain phenotype. Two additional studies with high
risk of bias demonstrated similar findings. A chronic pain
phenotype was defined using variables associated with
central sensitisation [23, 40] (e.g. quantitative sensory test-
ing (QST) [23]); pain and psychological profiling [31, 33].
The included studies demonstrated a high prevalence of
lower pain pressure threshold and enhanced mechanical
pain responses to temporal summation in several sites,
suggesting full manifestation of peripheral spreading and
central sensitization in a particular subgroup of KOA sub-
jects. Moreover, the presence of psychological distress;
poor coping style; sleep disturbance; fatigue; widespread
pain and illness burden signify the existence of complex
mechanisms that involve the entire body rather than the
knee as the “target” of the disease [23, 25, 31, 40]. These
features have a prevalence of 16 % to 19 % in the KOA
samples used in the aforementioned studies.
Inflammatory KOA
Two cohort studies and three cross-sectional studies
with low risk of bias identified specific subgroups of pa-
tients suggesting the existence of an inflammatory KOA
Table 3 Risk of bias assessment adapted from Hayden et al
Risk of Bias
Author Participation Attrition Prognostic Factors Outcome Confounding Analysis Total Score
Attur 2011 [18] Low Low Low Low Moderate Low Low
Bae 2010 [19] Moderate N/A Low Low Moderate Low Low
Berry 2010a [20] Moderate Moderate Low Low Moderate Moderate Low
Berry 2010b [21] Low Low Low Low Moderate Low Low
Blumnenfeld 2013 [22] Low Moderate Moderate Moderate Moderate Moderate Low
Cruz-Almeida 2013 [23] Moderate N/A Low Low Moderate Low Low
Doss 2007 [24] Moderate N/A Low Moderate Moderate Low Low
Egsgaard 2015 [25] Moderate N/A Low Low High Low High
Fernández-Tajes 2014 [26] Moderate N/A Low Moderate Moderate Moderate Low
Holla 2013 [27] Moderate Low Low Low Low Low Low
Jenkins 2015 [28] High N/A Moderate Moderate High Moderate High
Kerkhof 2008 [29] Low Low Low Low Moderate Low Low
Kinds 2013 [9] Moderate Low Low Low Moderate Moderate Low
King 2013 [30] High N/A High Low High Low High
Knoop 2011 [7] Low N/A Low Low Low Moderate Low
Murphy 2011 [31] Moderate N/A Low Moderate Moderate Low Low
Otterness 2000 [32] Moderate N/A Low Moderate Moderate Moderate Low
Pereira 2013 [33] Low N/A Moderate Low Moderate Low Low
Roemer 2012 [34] Low N/A Low Low Moderate Moderate Low
Sowers 2002 [35] Moderate Low Low Low Moderate Moderate Low
Van der Esch 2015 [36] Low N/A Low Low Moderate Low Low
Van spil 2012 [37] Moderate N/A Low Low Moderate Low Low
Waarsing 2015 [8] Low N/A Low Low Low Low Low
Iijima 2015 [38] Moderate N/A Low Low High Low High
Kittelson 2015 [40] Low N/A Low Low Low Low Low
N/A not applicable, the specific area of assessment was not applicable to the study
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phenotype, the prevalence of which varies in the differ-
ent samples from 16 % to 30 % [18, 24, 26, 32, 37]. Attur
et al. found a subgroup of KOA patients in which a gene
overexpression of inflammatory cytokines is present
(Interleukin-1B [IL-1β], Interleukin-8 [IL-8], cycloxygen-
ase 2[COX-2], GRO 2, macrophage inflammatory
protein-1α [MIP-1α] and -1β [MIP-1β]) [18]. These
patients had a higher level of pain at the baseline and
experienced faster radiographic progression compared to
the group with cytokine underexpression. Furthermore a
higher cytokine IL-6 concentration in the synovial fluid
has been found in a subgroup of people undergoing a
total knee (and hip) replacement [24]. The same cyto-
kine has also been found to be associated with other
inflammation markers (C-reactive protein [CR-P], tumor
necrosis receptor type I [TNFI] and tumor necrosis
receptor type II [TNFII], eosinophilic cationic protein
[ECP]) in an inflammatory phenotype identified through
a serum analysis [32]. Other inflammatory biomarkers
(Serum III procollagen peptide [sPIIINP], serum hyalur-
onic acid [sHA], sCOMP) characterise a subgroup found
by van Spil et al. with a higher synovial activity [37].
Metabolic syndrome
A metabolic phenotype characterized by variables sug-
gesting that a systemic metabolic syndrome contributes
significantly to the disease was supported by the litera-
ture Two longitudinal studies and two cross-sectional
studies, all with low risk of bias (Tables 2, 3 and 4)
[7, 35–37], suggest the existence of specific subgroups
of patients characterized by a higher prevalence of meta-
bolic factors (obesity, diabetes, hypertension and dyslipid-
emia) and a specific biomarker profile (plasma leptin
[pLeptin], High-Sensitivity C-RP, erythrocyte sedimentation
rate [ESR]) [7, 35–37]. These findings suggest the existence
of a metabolic syndrome phenotype.
Bone and cartilage metabolisms
Five studies (three longitudinal studies; two cross-
sectional studies) reported subgroups of participants
with alterations in bone and cartilage metabolism within
the knee joint [20, 22, 32, 34, 37]. Berry et al. found an
association between CTX-I; NTX-I and reduced cartil-
age lost in two subgroups, one characterized by high
levels of osteocalcin and the other by high levels of PINP
[20]. Van Spil et al. and Blumenfeld et al. found a cluster
of biomarkers associated with bone and cartilage metab-
olism (uCTX-I, uCTX-II, uNTX-I, sPINP, sOC, sCOMP)
[22, 37]. Additionally, Otterness et al. identified three
metabolic subgroups using bone markers (bone sialopro-
tein, hydroxylysyl pyridinoline, lysyl pyridinoline [BSP,
HP, LP], putative markers of cartilage anabolism (car-
boxypropeptide of type II [CPII], HA, epitope 846) and
catabolism (keratan sulfate [KS], COMP) [32]. Roemer
et al. used MRI to identify two rare phenotypes charac-
terised by hypertrophic and atrophic reactions of the
bone with a prevalence of 0.2 %-1.3 % respectively [34].
Evidence from these papers also suggests this may
constitute more than a single phenotype, including some
rare variations.
Mechanical overload
Four cross sectional studies with low risk of bias and
one with high risk of bias reported biomechanical
factors as main mechanisms of the disease in specific
KOA populations [7, 8, 19, 36]. From the data
extracted, these mechanisms seem responsible for the
disease in 12 %-22 % of the KOA population. Waarsing
et al. identified two subgroups in which biomechanical
stressors appear to be responsible for the disease [8].
One subgroup was characterized by degeneration of the
lateral compartment, valgus alignment, and lower BMI
while a high prevalence of previous injuries (55 %), a
severe degeneration of cartilage in the medial compart-
ment and varus malalignment represent the main
features in the other group. Knoop et al. and van der
Esch et al. found, using cluster analysis, a phenotype
with strong muscle strength, severe degeneration and
low BMI [7, 36], while Bae et al. identified two sub-
groups of KOA patients with full thickness cartilage
lesions in the medial and patella-femoral compartments
[19]. Overall, this phenotype appears to be character-
ized by excessive mechanical forces acting on specific
areas within the joint, causing KOA.
Minimal joint disease
Six studies with low risk of bias, of which three had a
longitudinal design and three a cross sectional design,
suggest the existence of a subgroup of KOA patients
whereby the disease is characterised by low degener-
ation, mild clinical symptoms and slow progression over
time (2–10 years) [7–9, 21, 27, 36]. One further study
with high risk of bias reported similar findings. Among
these seven studies, a combination of magnetic resonance
imaging (MRI) and biomarkers (serum cartilage oligo-
meric protein [sCOMP] , N-terminal propeptide of colla-
gen IIA [PIIANP]) [21]; x ray and clinical data [9, 27], and
cluster analysis (upper leg muscle strength, body mass
index (BMI), severity of radiographic OA, depressive
mood, radiographic scores of OA features, regional quan-
titative MRI measures of cartilage and bone, and self-
reported knee symptoms) [7, 36] were used to determine
the severity of the disease. Subjects were classified in this
phenotype according to the actual status of the disease
and the long term outcome (2–10 years). This phenotype
represents the only subgroup defined without regard to
the disease aetiology. Five studies reported or allowed the
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calculation of the prevalence in the KOA population of
these features that varied between 17 % and 47 %.
Discussion
The aim of the present study was to synthesize the current
evidence for the existence of clinical phenotypes in the
KOA population. Six main groups of variables which sug-
gest the existence of different underlying disease mecha-
nisms in the KOA population were identified after a
qualitative data analysis. These sets of variables should be
further explored in order to confirm and better define the
KOA phenotypes emerging from the literature.
In the chronic pain phenotype, high prevalence of
widespread pain and psychological disturbs suggests that
central sensitization plays a fundamental role in the dis-
ease process. Severe pain is often reported in association
with low or moderate degeneration of the local joint
structures. In these subjects, the joint disease alone is
not sufficient to explain the complex symptomatology,
thus it is likely that these subjects belong to a specific
KOA phenotype rather than to a stage of the disease
[7, 36]. Due to the reversibility of central sensitization
combined with the lack of longitudinal studies, it is
not yet clear if membership of this subgroup is stable
over time. Despite this uncertainty, when patients
present symptoms consistent with a chronic pain
phenotype, they may need and respond to treatments
that differ from those targeted towards joint pain [4].
Cognitive-behavioural therapy and pain education can
be worthwhile in this phenotype and may optimize
the results of other traditional intervention such as
exercise therapy and joint replacement [23].
In recent years, a growing body of evidence supports
the involvement of local inflammatory mediators in the
disease pathogenesis [41]. Signs of inflammation have
been found in a large part of the KOA population. In
Table 4 Appraisal of the evidence
Phenotypes
Author/year Chronic pain Inflammatory Metabolic syndrome Metabolic bone/cartilage Mechanical overload Minimal joint disease
Attur 2011 [18] ++
Bae 2010 [19] ++
Berry 2010a [20] ++
Berry 2010b [21] ++
Blumnenfeld 2013 [22] ++
Cruz-Almeida 2013 [23] ++
Doss 2007 [24] ++
Egsgaard 2015 [25] +
Fernández-Tajes 2014 [26] ++
Holla 2013 [27] ++
Jenkins 2015 [28] +
Kerkhof 2008 [29]
Kinds 2013 [9] ++
King 2013 [30] +
Knoop 2011 [7] ++ ++ ++ ++
Murphy 2011 [31] ++
Otterness 2000 [32] ++ ++
Pereira 2013 [33] ++
Roemer 2012 [34] ++
Sowers 2002 [35] ++
Van der Esch 2015 [36] ++ ++ ++ ++
Van Spil 2012 [37] ++ ++
Waarsing 2015 [8] ++ ++ ++
Iijima 2015 [38] +
Kittelson 2015 [40] ++
Total number of studies 6 (2) 5 4 5 4 (1) 6 (1)
+ high risk of bias, ++ low risk of bias
Total Number of Studies: low risk of bias (high risk of bias)
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many cases these signs seem only to characterize specific
phases of the disease [42]. From this literature review
emerged evidence that a subgroup of the KOA subjects
presents specific inflammatory mechanisms as determinant
of the disease. Attur et al. identified a group of KOA sub-
jects with a gene overexpression of inflammatory cytokines
in a study with longitudinal design [18]. This finding sug-
gests that KOA subgroups characterized by specific inflam-
mation mechanisms may exist regardless of disease stage,
as found in other studies [43, 44]. Treatments targeting the
inflammation process may be particularly effective in these
subjects [45].
Metabolic alterations seem key factors in two sub-
groups in which the alterations are present at a systemic
level or with regards only to bone and cartilage metabol-
ism in the affected knee joint [46, 47]. The included
studies reporting a metabolic syndrome as key characteris-
tic of a specific KOA subgroup used BMI; blood; and serum
biomarkers in their identification process. The use of these
features is supported by previous non-phenotyping studies
that identified an association between high BMI and OA
lesions in non-weight-bearing joints suggesting an under-
lying systemic pathway [48]. Moreover, recent studies
showed that the combination of cardio-metabolic disturb-
ance and obesity increases the risk of OA and identified an
association between OA and hypertension, dyslipidaemia,
and hyperglycaemia [46, 49–51]. These findings indicate
that systemic metabolic alterations could be one of the
main causes for the disease in a specific subgroup of sub-
jects. A multi-stages disease model cannot fully explain the
existence of a metabolic syndrome subgroup that instead
could be explained as a separate KOA phenotype.
Metabolic alterations in the KOA population have
been reported not only at a systemic level, but as specific
alterations in cartilage and bone metabolism. Biomarker
analysis represents the gold standard for the identifica-
tion of metabolic alterations in bone and cartilage. The
identification of specific biomarkers profiles in the KOA
population, as emerged from the studies included in this
review, which represents strong evidence in support of
the existence of a phenotype in which bone and cartilage
metabolism are of primary importance as a determinant
of the disease. Drugs aiming to influence bone and car-
tilage metabolism may see their effect improved if tested
in this specific phenotype [4].
The possibility of a mechanical overload phenotype
emerged from this systematic review; however, a large gap
in the evidence regarding the existence of this phenotype
emerged, due also to the lack of studies with longitudinal
design. Among the studies included, malalignment and
muscle strength were the biomechanical variables used to
define biomechanical phenotypes [7, 8, 36] in combination
with cartilage degeneration, BMI, and previous injuries.
Malalignment has been shown to be strongly associated
with disease progression and cartilage degeneration in
specific compartments of the knee (e.g. varus malalign-
ment is closely associated with medial tibiofemoral
compartment disease) [52]; while high muscle strength
has been reported as a protective factor against symp-
tomatic but not radiographic KOA [53]. The studies in-
cluded in this systematic review reported subgroups of
KOA subjects with high levels of muscle strength. The
authors suggested that the presence of high level of
muscle strength in combination with other factors (e.g.
malalignment, previous injury, BMI) could signify a
group of people with high level of physical activity and
biomechanical overload [8]. Therefore, malalignment in
combination with other known factors (e.g. muscle
strength, previous injury) may confer high local stress
in the correspondent joint compartment supporting the
hypothesis of biomechanical mechanisms responsible
for the disease. For this reason, it is likely that these
subjects would respond to, biomechanical interventions
(e.g. wedged insoles, knee braces) rather than to drug
treatments aiming to protect the cartilage [4].
Although our study aimed to identify phenotypes based
on different disease mechanisms, from the literature a
group of subjects with low degeneration and mild clinical
symptoms emerged. These subjects seem to suggest the
existence of a KOA subgroup characterized by minimal
joint disease. Although these features could be considered
representing an early stage of the disease; three of the
included studies showed stability over time (2–10 years)
[9, 20, 27], supporting the consideration of this sub-
group as a phenotype rather than a stage of the disease.
Subjects were classified in this group based on the se-
verity and the outcome of the disease regardless of pos-
sible mechanisms or aetiology. Despite this, the clinical
characteristics of the subjects classified in this subgroup
seem to suggest different underling mechanisms of the
disease. The inclusion of outcomes in the classification
process makes the identification of subjects belonging
to this phenotype difficult in clinical practice. Strong
evidence of a clinical variable able to predict the non-
progression of the disease is still missing.
In this systematic review, six groups of variables that
can indicate the presence of six main phenotypes have
been identified. These sets of variables seem to suggest
the existence of different disease mechanisms and aeti-
ology in specific subgroups of the KOA population. None
of the studies analysed here explored the possibility of an
overlap between the suggested subgroups. Considering
the variables used to identify phenotypes and the patho-
physiology of the disease, there is no reason to exclude the
possibility of an overlap. For example, patients with
chronic pain could present characteristics considered key
factors of other phenotypes like metabolic alterations or
malalignment. Therefore, while these phenotypes may be
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distinct, they are not necessarily mutually exclusive. It can
be hypothesized that patients with features consistent with
more than one phenotype may be more severely affected
by the disease and could be regarded as more complex
clinical cases.
Another implication of the overlap between phenotypes
is the possibility that the phenotypes identified here do
not exist as separate entities in the KOA population, but
only as result of the choice of specific variables, samples
and analysis in the phenotyping process. This represents a
limitation of the review that is not able to conclude if
these phenotypes can be regarded as separate entities.
Therefore, studies that try to identify KOA phenotypes
with different disease mechanisms within the same sample
are needed to study the possibility and the entity of over-
lap between phenotypes and verify the existence of pheno-
types as distinct groups. Moreover, studies identifying an
overlap between phenotypes may be important in the
identification of complex KOA cases that may benefit
from a combined treatment approach.
Among the 25 studies included, four had a strong risk
of bias [25, 28, 30]. The main source of bias was the
presence of confounding factors; of all the studies in-
cluded in the review, only four studies presented a low
risk of bias in that specific area [7, 8, 27, 40]. Disease
duration was the main confounding factor taken into ac-
count in this systematic review, whereby differences be-
tween patients due to them being in different stages of
the same disease process could potentially identify sub-
groups. These disease-stage subgroups did not fit the
definition of phenotypes for the purpose of this review.
Therefore, studies in which there were significant differ-
ences in disease duration between identified subgroups
were regarded as at high risk of bias in this area.
Two of the included studies using blood and serum bio-
markers in order to identify phenotypes had a mixed sam-
ple of KOA and hip OA [24, 37]. In both the samples more
than 70 % of the subject had a diagnosis of KOA, but
nevertheless findings from these studies should be inter-
preted with caution when applied to the KOA population.
Another important source of bias was the selection of
the study sample. Studies that tried to identify specific
phenotype may have oversampled high-risk patients,
thus leading to elevated prevalence rates. A similar bias
was the inclusion of only patients listed for joint replace-
ment [24, 26, 28]. Furthermore, the evidence presented
in this review is limited by the research focus of pub-
lished studies and their quality. The criterion used to
identify a phenotype required the support of two studies
with low or moderate risk of bias. This approach implies
the possibility that some important phenotypes have not
been reported due to a limited number of appropriate
studies (as was hypothesized to be the case for the
mechanical overload phenotype to some extent).
Because OA is a heterogeneous disease, identifying
subgroups for treatments is probably one of the promis-
ing ways forward in clinical research [2]. This can only
be achieved when the correct methodology to identify
such subgroups is used. For this reason, we focused only
on studies that had as a main focus the identification of
KOA phenotypes. Some studies looking at the influence
of specific risk factors of disease progression and out-
come were excluded. We are aware that results emer-
ging from these studies may identify useful evidence,
especially in generating new hypotheses regarding phe-
notypes. Nevertheless, the aim of this review was the
identification of phenotypes which have already been
broadly studied in the literature and that are supported
by evidence emerging from these studies. The absence
of a post traumatic KOA as an identified phenotype may
work as an example. Only Waarsing et al. analysed the
rate of knee injuries to characterize their phenotype.
Despite the strong evidence that identifies injuries as an
important risk factor in the development of KOA; stud-
ies investigating whether patients can be meaningfully
grouped based on a history of traumatic injury are ab-
sent. It may be that subjects with a history of traumatic
knee injury constitute a separate phenotype. Alterna-
tively, injuries may predispose patients to KOA through
more than one underlying pathway, and may therefore
not be a meaningful phenotypic identifier in itself.
The lack of a clear definition of phenotypes makes
synthesis of the current literature difficult; therefore, a
clear and shared definition of KOA phenotypes would
help to better direct future research in the field. To
combine studies, we relied on what was reported by the
author and on previous research on KOA risk and
aetiologic factors. This approach has intrinsic risks and
may be affected by a decisional bias. However, all the
data used to draw the conclusions have been reported
(see Additional file 1) in the attempt to make the deci-
sion process as transparent as possible. We found this
methodology the best compromise to deal with the large
variability in the field and to provide useful evidence.
Finally, the six sets of variables identified in this review
may not be able to fully explain heterogeneity of the
patient population. Future research may yet lead to the
identification of different disease mechanisms suggesting
the existence of new phenotypes.
Conclusions
Six main sets of variables suggesting the existence of six
clinical phenotypes of KOA characterized by different
disease mechanisms were identified in this systematic re-
view: chronic pain; inflammatory; metabolic syndrome;
bone and cartilage metabolism; mechanical overload and
minimal joint disease. This represents a good starting
point for future research aiming to better identify KOA
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phenotypes. Furthermore, this process of synthesis of
evidence may be relevant in the development of better
treatment allocation and clinical disease management.
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